Tumor-Associated Lacto-series Antigen Production Service

Tumor-Associated Lacto-series Antigen Production Service at CD BioGlyco

The surfaces of cancer cells exhibit a range of antigenic carbohydrate structures known as tumor-associated carbohydrate antigens (TACAs). TACAs can be categorized into two classes: glycolipid antigens and glycoprotein antigens. Among glycolipids, there are several families, two of which include lacto-series antigens, and neolacto-series antigens.

Fig.1 A variety of antigenic carbohydrate structures. (CD BioGlyco)

Because of the important role of lacto-series antigens in cancer research, as well as their potential applications in the research of therapeutics and detection, lacto-series antigen products have an essential role to take forward for vaccine development. Based on these needs and our highly advanced R&D team, CD BioGlyco has developed an antigen production service based on biological or chemical synthesis, especially for lacto-series antigens. Here are some of the excellent and popular lacto-series antigen production services. Besides, CD BioGlyco also provides other Tumor-Associated Glycolipid Antigen Production Services for clients that help study Tumor-Associated Carbohydrate Vaccine Development.

Tumor-Associated Le^a Antigen Production Service

Le^a antigen is a tetra-saccharide structure consisting of four sugar residues linked together. The specific structure of Le^a is Galβ1-3(Fucα1-4)GlcNAcβ1-R.

Tumor-Associated SLe^a Antigen Production Service

SLe^a antigen is a modification of Le^a with the addition of sialic acid. Its specific structure is NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-R.

Tumor-Associated Le^b Antigen Production Service

Le^b antigen is also a tetra-saccharide structure, and its specific structure is Galβ1-3(Fucα1-4)[GlcNAcβ1-3]Galβ1-R.

At CD BioGlyco, we have established a professional and comprehensive production process of tumor-associated lacto-series antigen production service. Producing lacto-series antigens involves the chemical synthesis of specific carbohydrate structures, here are the general steps to produce these antigens.

Fig.2 Standard process of lacto-series antigens production. (CD BioGlyco)

Publication Data

Technology: TACAs, Anti-cancer Vaccine Development

Journal: Journal of Carbohydrate Chemistry

IF: 1

Published: 2012

Results: The current focus on developing anti-cancer vaccines based on carbohydrates is a topic of great interest. This review provides an overview of the latest advancements in this dynamic field. It begins with an introduction to tumor-associated carbohydrate antigens and their interaction with the immune system. The review then delves into the diverse strategies that have been devised to boost the immunogenicity of these antigens. Additionally, it discusses the findings from animal studies and clinical trials in this context.

Fig.3 Tn(c)-KLH vaccine. (Yin & Huang, 2012)

Roles of Lacto-series Antigens in Cancer

Lacto-series antigens, particularly Le^a and Le^b, are overexpressed in various cancer types. They are associated with cancer progression and metastasis. These antigens are often found on the surfaces of cancer cells and can be involved in several cancer-related processes.

Lacto-series antigens on cancer cells can interact with selectins on the surface of endothelial cells, promoting cancer cell adhesion and facilitating metastasis by aiding in the binding of circulating tumor cells to distant tissues.
These antigens can help cancer cells evade immune surveillance by interfering with immune responses, contributing to tumor immune escape.
Detection of lacto-series antigens in patient samples can be used for cancer diagnosis and prognosis.
Targeting the interactions involving lacto-series antigens and selectins has been explored as a potential strategy for cancer treatment and prevention of metastasis.

Advantages of Us

We have a professional Glyco™ Vaccine Development Service Platform for clients and provide custom tumor-associated carbohydrate vaccine development services.
We have a well-equipment lab for our tumor-associated glycolipid antigen production and we aim to offer the A-level and high-quality products for our clients.

CD BioGlyco has established a first-class R&D team to provide our clients with strong support for their sugar-related research and development and professional custom services. If our services appeal to you and you would like to discuss the possibility of working with us further, please do not hesitate to contact us!

Reference

Yin Z.; Huang X. Recent development in carbohydrate-based anti-cancer vaccines. J Carbohydr Chem. 2012, 31(3): 143-186.

This service is for Research Use Only, not intended for any clinical use.

Tumor-Associated Lacto-series Antigen Production Service